CRABP1-reduced expression is associated with poorer prognosis in serous and clear cell ovarian adenocarcinoma

PurposeCRABP1 is a modulator of retinoic acid function. The aim of the present study was to investigate CRABP1 expression and its clinical significance in ovarian carcinoma.MethodsExpression of CRABP1 protein was investigated by immunohistochemical analysis in 100 ovarian carcinomas of various histological sub-types, including serous and clear cell adenocarcinomas. Relationship of CRABP1 expression to clinical features, including prognosis, was analyzed.ResultsReduced expression of CRABP1 protein was detected especially frequently in the serous and clear cell adenocarcinomas sub-types, 50% (20 of 40) and 38% (10 of 26) of cases, respectively. We found that in both serous and clear cell adenocarcinomas overall survival was significantly poorer in the cases with reduced CRABP1 expression compared to similar cases where expression was maintained, irrespective of the disease stage (P = 0.0073 and 0.049, respectively). Disease-free survival of the serous and clear cell adenocarcinoma cases with reduced CRABP1 expression was significantly poorer, compared to the cases whose CRABP1 expression was maintained (P = 0.024). Multivariate analysis showed that reduced expression of CRABP1 was a significantly important prognostic factor (adjusted hazard ratio: 8.189 (95% CI, 2.186–30.672, P = 0.0019)).ConclusionsThe present study is the first to demonstrate that the reduced expression of CRABP1 has a potential as a prognostic marker for serous adenocarcinoma which is the most frequent histological ovarian tumor type and also for clear cell carcinoma that often exhibits chemo-resistance. Further study is necessary to clarify how CRABP1 protein expression was altered and how CRABP1 affects ovarian carcinoma cells.

[1]  L. Gudas,et al.  The level of CRABP-I expression influences the amounts and types of all-trans-retinoic acid metabolites in F9 teratocarcinoma stem cells. , 1992, The Journal of biological chemistry.

[2]  Huiling He,et al.  Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion , 2007, Proceedings of the National Academy of Sciences.

[3]  A. de la Chapelle,et al.  Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma , 2003, International journal of cancer.

[4]  J. Inazawa,et al.  Frequent methylation-associated silencing of a candidate tumor-suppressor, CRABP1, in esophageal squamous-cell carcinoma , 2007, Oncogene.

[5]  Stephen J. Williams,et al.  Vitamin A metabolism is impaired in human ovarian cancer. , 2009, Gynecologic oncology.

[6]  Mitsuaki Suzuki,et al.  Clinical characteristics of clear cell carcinoma of the ovary , 2000, Cancer.

[7]  L. Rosanò,et al.  Epithelial-Mesenchymal Transition in Ovarian Cancer Progression: A Crucial Role for the Endothelin Axis , 2007, Cells Tissues Organs.

[8]  J. Thompson,et al.  Transcriptional regulation of the cellular retinoic acid binding protein I gene in F9 teratocarcinoma cells. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[9]  A. Parwani.  ALDH1 expression correlates with favorable prognosis in ovarian cancers , 2010 .

[10]  D. Katsaros,et al.  Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer , 2004, International Journal of Gynecologic Cancer.

[11]  N. Probst-Hensch,et al.  Prognostic Significance of Epithelial-Mesenchymal and Mesenchymal-Epithelial Transition Protein Expression in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[12]  H. Shim,et al.  Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma. , 2009, Human pathology.

[13]  Takako Yamada,et al.  Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin. , 2006, Cancer letters.

[14]  Y. S. Kim,et al.  Prognostic Implications of and Relationship Between CpG Island Hypermethylation and Repetitive DNA Hypomethylation in Hepatocellular Carcinoma , 2009, Clinical Cancer Research.

[15]  Robert Brown,et al.  Hypermethylation of 18S and 28S Ribosomal DNAs Predicts Progression-Free Survival in Patients with Ovarian Cancer , 2005, Clinical Cancer Research.

[16]  N. Martinet,et al.  Vitamin A/retinoids signalling in the human lung. , 2009, Lung cancer.

[17]  R. Kurman,et al.  BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT , 1995 .

[18]  Ji-Ying Song,et al.  A Twist-Snail Axis Critical for TrkB-Induced Epithelial-Mesenchymal Transition-Like Transformation, Anoikis Resistance, and Metastasis , 2009, Molecular and Cellular Biology.

[19]  Qinghua Wu,et al.  DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets , 2007, Molecular Cancer.

[20]  Kathleen R. Cho,et al.  Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. , 1997, Cancer research.

[21]  I. Gitelman,et al.  CHAPTER 2 A Twist – Snail axis critical for TrkB-induced EMT-like transformation , anoikis resistance and metastasis , 2011 .

[22]  P. Disaia,et al.  Clinical Gynecologic Oncology , 1981 .

[23]  Jonathan S. Berek,et al.  Novak's Gynecology , 1996 .

[24]  A. LaMantia,et al.  Mesenchymal/epithelial regulation of retinoic acid signaling in the olfactory placode. , 2003, Developmental biology.

[25]  Susan J Clark,et al.  DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. , 2008, Gynecologic oncology.

[26]  B. Thisse,et al.  Retention of the duplicated cellular retinoic acid‐binding protein 1 genes (crabp1a and crabp1b) in the zebrafish genome by subfunctionalization of tissue‐specific expression , 2005, The FEBS journal.

[27]  T. Dønnem,et al.  The prognostic impact of NF-κB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer , 2008, British Journal of Cancer.